ArticleRSC advances2026
Comprehensive study of tunable BiOI/BiOBr heterojunctions: reactive species and mechanistic insights for visible-light degradation of indigo carmine.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, heterojunction composites of bismuth-based oxyhalides (BiOX, X = F/Cl/Br/I) have emerged as effective visible-light-driven photocatalysts. Despite notable advances, particularly the promising performances of bulk BiOI/BiOBr in degrading methyl orange and the synergistic effects observed in their thin films for indigo carmine (IC) photodegradation, key gaps still persist. These include the lack of a comprehensive investigation into simple, tunable bulk BiOI/BiOBr heterojunctions and the insufficient elucidation of reactive species for charge-transfer mechanisms governing dye remediation. This study introduces a facile and scalable approach for synthesizing bulk BiOI/BiOBr heterostructures
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.